Weight loss outcomes with semaglutide 2.4 mg in moderate or severe obesity in step 1 and 2
C. Le Roux; A. Aminian; R. Batterham; D. Hesse; C. Jensen; B. McGowan; A. Pakseresht; G. Rigas Sydney; F. Rubino; S. Taheri; et al.
Year of publication
Obesity (Silver Spring, Md.)
Background: Conventional lifestyle and pharmacologic interventions alone result in only modest long‐term weight loss in patients with moderate‐to‐severe obesity. We evaluated outcomes with semaglutide 2.4 mg in the STEP 1 and 2 trials for this specific population. Methods: In STEP 1 and 2, adults with overweight or obesity (and with type 2 diabetes in STEP 2 only) were randomized to onceweekly subcutaneous semaglutide 2.4 mg or placebo, both plus lifestyle intervention. This post‐hoc analysis included participants with Class II obesity (body mass index [BMI] ≥35‐